Combining retatrutide with another GLP-1 agonist (semaglutide, tirzepatide) is not recommended because the receptor overlap increases side effects without proportional benefit
The development of further dual GLP-1/GIP receptor agonists seems to be a promising next step in managing various cardiovascular disease
N., Angelopoulou, E., Piperi, C., Shaikh, M
At our Upper East Side practice, patients arent just asking how to lose a substantial amount of weighttheyre asking how to feel more in control of the changes that come with time: increased inflammation in the face and body, high cholesterol levels, or stubborn visceral fat
healthy people over 100 years of age have significantly higher levels of glutathione than the general population